Bioterrorism Agents — Clinical Approach

Bioterrorism is the deliberate release of biological agents (bacteria, viruses, toxins) to cause illness, death, fear, social disruption, or economic damage. The Centers for Disease Control and Prevention (CDC) classifies bioterrorism agents into three categories based on potential threat: Category A (highest priority — easily disseminated or transmitted person-to-person, high mortality, public panic, requires special public health preparedness): anthrax (Bacillus anthracis), smallpox (variola virus, eradicated but stockpiled), plague (Yersinia pestis), tularemia (Francisella tularensis), botulism (Clostridium botulinum toxin), viral hemorrhagic fevers (filoviruses Ebola/Marburg, arenaviruses Lassa/Junin/Machupo, bunyaviruses CCHF/Rift Valley fever). Category B (second-highest priority — moderate morbidity, low mortality, requires enhanced diagnostics and surveillance): brucellosis (Brucella species), epsilon toxin (Clostridium perfringens), food safety threats (Salmonella, Shigella, E. coli O157:H7), glanders (Burkholderia mallei), melioidosis (Burkholderia pseudomallei), psittacosis (Chlamydia psittaci), Q fever (Coxiella burnetii), ricin toxin (Ricinus communis), staphylococcal enterotoxin B, typhus (Rickettsia prowazekii), viral encephalitides (Venezuelan, eastern, western equine encephalitis viruses), water safety threats (Vibrio cholerae, Cryptosporidium parvum). Category C (emerging pathogens — could be engineered for mass dissemination): Nipah virus, hantavirus, tickborne hemorrhagic fever, yellow fever, multidrug-resistant tuberculosis, antimicrobial resistance.

Anthrax (Bacillus anthracis): three forms — cutaneous (most common, painless ulcer with black eschar, 95% recoverable with treatment), inhalational (most lethal, biphasic illness with flu-like prodrome followed by fulminant respiratory failure with mediastinitis, hemorrhagic mediastinal lymphadenitis on CXR, mortality 45-90%), gastrointestinal (rare, oropharyngeal or intestinal lesions, mortality 25-60%). Treatment: ciprofloxacin or doxycycline plus 1-2 additional antimicrobials (clindamycin for toxin production inhibition, rifampin, vancomycin, or beta-lactam if susceptibility), anthrax antitoxin (raxibacumab, obiltoxaximab, anthrax immune globulin) for severe disease, supportive care. Post-exposure prophylaxis: ciprofloxacin or doxycycline 60 days plus 3-dose anthrax vaccine (BioThrax/AVA) series. Smallpox: rash with synchronous lesions all in same stage of development on face/extremities (centrifugal distribution, contrasts to varicella centripetal asynchronous), 30% mortality, treatment with tecovirimat (Tpoxx), brincidofovir, vaccinia immune globulin, ring vaccination of contacts. Plague: bubonic (regional lymphadenitis with painful bubo, fever, mortality 50% untreated), septicemic (gram-negative sepsis without bubo, mortality 90% untreated), pneumonic (most concerning for bioterrorism, person-to-person via respiratory droplets, mortality near 100% without rapid treatment) — treatment with streptomycin, gentamicin, doxycycline, ciprofloxacin, ceftriaxone; post-exposure prophylaxis with doxycycline or ciprofloxacin 7 days.

Tularemia: typhoidal/pneumonic forms most concerning for bioterrorism, treatment with streptomycin, gentamicin, doxycycline, ciprofloxacin. Botulism: descending flaccid paralysis with cranial nerve involvement, treatment with antitoxin (heptavalent botulinum antitoxin, BabyBIG for infants), supportive care including mechanical ventilation. Viral hemorrhagic fevers: high-level isolation (BSL-4), supportive care, ribavirin for arenaviruses (Lassa) and bunyaviruses (CCHF), no specific treatment for filoviruses though monoclonal antibodies (Inmazeb, ebanga) for Ebola Zaire. Recognition principles: high index of suspicion for unusual presentations (anthrax in non-occupational case, smallpox-like rash, multiple cases of similar illness, unusual clinical or epidemiologic patterns, primary pneumonic plague without rodent exposure), rapid syndromic recognition (acute respiratory failure, rash with fever, neurologic syndromes, hemorrhagic syndromes), bioterrorism considerations in emergency departments and primary care. Response: immediate infection control isolation (airborne, contact, droplet as appropriate), notification of public health authorities (state and federal), coordination with FBI for criminal investigation, decontamination if indicated, post-exposure prophylaxis for contacts, surveillance for additional cases, mass casualty preparedness, vaccination strategies (ring, mass), antitoxin and antimicrobial Strategic National Stockpile (SNS) deployment, healthcare worker protection (PPE, prophylaxis), risk communication to public, mental health support.